BioMimetic disclosed in its 3Q12 earnings that it submitted a Device License Application (DLA) to Health Canada for Augment Injectable Bone Graft. In June, BioMimetic reported data from a Canadian pivotal trial to treat foot...

A pivotal Canadian trial in 217 patients showed that Augment Injectable Bone Graft met the primary endpoint of non-inferiority to autograft in the proportion of patients who achieved >=50% osseous bone bridging as evaluated by...

BioMimetic disclosed in its 4Q11 earnings that it voluntarily suspended screening and enrollment in a North American Phase III trial evaluating its Augment Injectable Bone Graft to focus on Augment Bone Graft. In January, the...

In its 3Q11 earnings, BioMimetic said it proposed to expand enrollment to 300 patients in a North American Phase III trial evaluating its Augment Injectable Bone Graft to treat hindfoot fusions. The trial had been...

Initial data from an open-label, Canadian pilot trial of Augment Injectable Bone Graft in 10 patients showed 100% clinical success based on measurements including ability to stand and walk without pain at 6-months post-surgery. The...

When OSI (OSIP) announced plans to buy Eyetech last year, angry shareholders took their pound of flesh by immediately driving the stock price down 22%. Their gripe was that they didn't think OSIP was buying...